Latest Timolol Stories
Othera Pharmaceuticals, Inc., today announced that it has initiated dosing in a Phase I/II clinical trial to determine the safety and efficacy of topical OT-730 in patients with ocular hypertension and glaucoma.
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that the Company filed a complaint in the U.S. District Court for the District of Columbia against the U.S.
Othera Pharmaceuticals has submitted an investigational new drug application to the FDA for OT-730, an oculoselective beta-blocker, as a potential treatment for glaucoma. A Phase I-II safety and efficacy trial is planned for completion by the end of 2008.
Othera Pharmaceuticals, Inc., announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for OT-730, an oculoselective beta-blocker, as a potential treatment for glaucoma.
FDC has received approval from the FDA for its abbreviated new drug application, Ciprofloxacin ophthalmic solution. FDC's Ciprofloxacin Ophthalmic Solution is a broad spectrum antibiotic used for occular surface infections.